The Fully Human Anti-CD47 Antibody SRF231 Has Dual-Mechanism Antitumor Activity Against Chronic Lymphocytic Leukemia (CLL) Cells and Increases the Activity of Both Rituximab and Venetoclax

Rebecca Valentin, MD; Marisa O. Peluso, MS; Timothy Z. Lehmberg, BA; Ammar Adam, DVM; Li Zhang, MA; Caroline L. Armet, BS; Jennifer L. Guerriero, PhD; Benjamin H. Lee, MD, PhD; Vito J. Palombella, PhD; Pamela M. Holland, PhD; Alison M. Paterson, PhD; Matthew S. Davids, MD, MMSc

*Contribution equally: Department of Medical Oncology, Dana-Farber Cancer Institute (DFCI), Boston, MA, USA; Surface Oncology, Cambridge, MA, USA

**SIAM on Cancer 2017 Annual Meeting**

**Scaffolded Antibody**

**Solute Antibody**

**SRF231 INDUCES CELL DEATH IN PRIMARY CLL CIRCULATING ANTIC masses MECHANISM THAT DEPENDS PARTIALLY ON PLCG2**

**SRF231 TREATMENT RESULTS IN BOTH INCREASED PHAGOCYTOSIS AND INCREASED CELL DEATH IN MACROPHAGE CO-CULTURES**

**SRF231 TREATMENT INCREASES THE EFFECT OF RTX AND VEN IN VITRO**

**SBF231 ENHANCES MACROPHAGE-MEDIATED PHAGOCYTOSIS OF RTX-TREATED CLL CELLS**

**SBF231 DISPLAYS PROFOUN ANTITUMOR ACTIVITY IN A XENOGR Model OF B-CELL LYMPHOMA AS A SINGLE AGENT AND IN COMBINATION WITH VEN**

**SRF231 TREATMENT INCREASES THE EFFECT OF VEN IN VIVO**

**SRF231 INDUCES CASPASE-INDENICATE MECHANISM DEATH IN PRIMARY CLL CELLS**

**SRF231 INDUCES TUMOR CELL LINE DEATH UPON ANTIBODY SCAFFOLDING**

**SRF231 INDUCES CELL DEATH UNDER SCAFFOLDING CONDITIONS IN PRIMARY CLL CELLS**

**EXPERIMENTAL DESIGN**

**METHODS**

**CONCLUSIONS**

**REFERENCES**

**The Fully Human Anti-CD47 Antibody SRF231 Has Dual-Mechanism Antitumor Activity Against Chronic Lymphocytic Leukemia (CLL) Cells and Increases the Activity of Both Rituximab and Venetoclax**

**REFERENCES**

**The Fully Human Anti-CD47 Antibody SRF231 Has Dual-Mechanism Antitumor Activity Against Chronic Lymphocytic Leukemia (CLL) Cells and Increases the Activity of Both Rituximab and Venetoclax**

**REFERENCES**

**The Fully Human Anti-CD47 Antibody SRF231 Has Dual-Mechanism Antitumor Activity Against Chronic Lymphocytic Leukemia (CLL) Cells and Increases the Activity of Both Rituximab and Venetoclax**

**REFERENCES**

**The Fully Human Anti-CD47 Antibody SRF231 Has Dual-Mechanism Antitumor Activity Against Chronic Lymphocytic Leukemia (CLL) Cells and Increases the Activity of Both Rituximab and Venetoclax**